API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com/news-release/2024/08/06/2925031/0/en/TFF-Pharmaceuticals-Provides-Continued-Positive-Outcomes-from-Tacrolimus-Inhalation-Powder-TFF-TAC-Phase-2-Trial-for-the-Prevention-of-Lung-Transplant-Rejection.html
https://www.globenewswire.com/news-release/2024/06/24/2902869/0/en/TFF-Pharmaceuticals-Provides-Regulatory-Update-on-Tacrolimus-Inhalation-Powder-TFF-TAC-Clinical-Program-for-the-Prevention-of-Lung-Transplant-Rejection.html
https://www.globenewswire.com/news-release/2024/05/15/2882269/0/en/TFF-Pharmaceuticals-Provides-Update-on-Tacrolimus-Inhalation-Powder-TFF-TAC-Phase-2-Trial-for-the-Prevention-of-Lung-Transplant-Rejection.html
https://www.globenewswire.com/news-release/2024/04/29/2871365/0/en/TFF-Pharmaceuticals-Makes-Available-Phase-2-Data-from-Tacrolimus-Inhalation-Powder-TFF-TAC-for-the-Prevention-of-Lung-Transplant-Rejection-Presented-at-the-Recent-ISHLT-Annual-Meet.html
https://www.indianpharmapost.com/news/biocon-receives-approval-from-sahpra-for-tacrolimus-capsule-15548
https://www.globenewswire.com/news-release/2024/04/15/2862639/0/en/TFF-Pharmaceuticals-Announces-Additional-Positive-Data-from-the-Tacrolimus-Inhalation-Powder-TFF-TAC-Phase-2-Trial-Following-Oral-Presentation-at-the-ISHLT-44th-Annual-Late-Breakin.html
https://www.globenewswire.com/news-release/2024/03/27/2853586/0/en/TFF-Pharmaceuticals-Announces-Updated-Data-from-the-Tacrolimus-Inhalation-Powder-TFF-TAC-and-Voriconazole-Inhalation-Powder-TFF-VORI-Clinical-Programs.html
https://www.globenewswire.com/news-release/2024/03/25/2851685/0/en/TFF-Pharmaceuticals-Announces-Oral-Presentation-of-Interim-Data-from-the-Phase-2-Study-of-Tacrolimus-Inhalation-Powder-TFF-TAC-for-the-Prevention-of-Lung-Transplant-Rejection-at-th.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-1-2023-82562.pdf
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=11202310416
https://www.fiercebiotech.com/biotech/regimmune-touts-compelling-phase-2-data-stem-call-transplant-patients-readies-phase-3
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-10-2022-1660649426.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-15-2022-1655268880.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-tacrolimus-1653045430.pdf
https://www.biospace.com/article/releases/the-product-monograph-for-protopic-has-been-updated/?s=71
https://www.biospace.com/article/releases/the-product-monograph-for-protopic-has-been-updated/?s=71
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203740
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213112
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212297
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206662
https://markets.businessinsider.com/news/stocks/deciphera-presents-data-from-qinlock-ripretinib-program-at-the-connective-tissue-oncology-society-ctos-2020-virtual-annual-meeting-1029791271
https://www.biospace.com/article/releases/tff-pharmaceuticals-updates-progress-of-human-clinical-trial-with-tacrolimus-inhalation-powder/
https://www.sandoz.com/news/media-releases/sandoz-launches-once-daily-generic-tacrolimus-transplant-patients-europe#:~:text=Sandoz%20launches%20once%2Ddaily%20generic%20tacrolimus%20for%20transplant%20patients%20in%20Europe,-Jun%2004%2C%202020&text=Holzkirchen%2C%20June%204%2C%202020%20%E2%80%93,as%20Conferoport%C2%AE%20in%20Spain.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211688
https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-orgs/documents/document/ucm628656.pdf
http://www.pharmatimes.com/news/astellas,_sunovion_and_shield_breach_abpi_code_1272923
https://www.prnewswire.com/news-releases/auritec-pharmaceuticals-completes-enrollment-for-its-sustained-release-depot-tacrolimus-clinical-trial-300752173.html
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/list-centrally-authorised-products-requiring-notification-change-update-annexes_en-0.pdf
https://globenewswire.com/news-release/2018/04/19/1482229/0/en/FDA-Accepts-Veloxis-s-Supplemental-New-Drug-Application-for-the-De-Novo-Indication-for-ENVARSUS-XR.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210393
https://www.prnewswire.com/news-releases/veloxis-announces-the-publication-of-asertaa-a-study-of-extended-release-tacrolimus-in-african-americans-a-phase-iiib-study-of-envarsus-xr-300621315.html
https://www.pharmacompass.com/pdf/news/teva-bv-tacforius-tacrolimus-receives-approval-in-europe-1517031773.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206651
http://www.pmlive.com/pharma_news/chmp_recommends_tevas_generic_version_of_astellas_advagraf_1208467
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203900
http://www.biospectrumasia.com/news/25/9019/veloxis-signs-agreement-with-italys-chiesi.html
https://globenewswire.com/news-release/2017/06/06/1008350/0/en/Veloxis-Pharmaceuticals-A-S-Announces-Agreement-with-Chiesi-Farmaceutici-S-p-A-to-Commercialize-Envarsus-XR-in-China.html
http://www.prnewswire.com/news-releases/veloxis-pharmaceuticals-as-and-endo-ventures-limited-jointly-announce-agreement-for-paladin-labs-inc-to-commercialize-envarsus-xr-in-canada-300469735.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-22-2017-1490161550.pdf
http://www.pharma-excipients.ch/2016/08/09/loading-of-tacrolimus-containing-lipid-based-drug-delivery-systems-into-mesoporous-silica-for-extended-release/
http://www.pharma-excipients.ch/2016/05/02/using-supercritical-fluid-technology-sft-in-preparation-of-tacrolimus-solid-dispersions/
http://www.prnewswire.com/news-releases/veloxis-launches-envarsusxr-for-treatment-of-kidney-transplant-patients-in-us-300187845.html
http://www.prnewswire.com/news-releases/biologictx-is-a-proud-pharmacy-provider-for-envarsus-xr-300186341.html
http://www.biospace.com/News/leo-pharma-puts-up-675-million-for-astellass/399023/source=TopBreaking
http://www.prnewswire.com/news-releases/veloxis-announces-publication-of-phase-iii-b-strato-study-of-envarsus-xr-demonstrating-reduction-in-hand-tremors-compared-to-twice-daily-tacrolimus-in-kidney-transplant-patients-300145889.html
http://www.news-medical.net/news/20150711/Envarsus-XR-receives-FDA-approval-for-treatment-of-kidney-transplant-recipients.aspx?utm_source=twitterfeed&utm_medium=twitter&utm_campaign=DTN+Pharma+News:
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/06/district-court-rules-for-fda-in-battle-over-the-scope-of-3-year-exclusivity-in-the-context-of-duelin.html
http://www.fiercepharma.com/story/astellas-dodges-trial-over-alleged-prograf-generics-delay/2015-01-21